ITCH RELIEF

Name: Nemluvio HCP
Creator: Nemluvio

NEMLUVIO delivers fast and lasting itch relief for patients with PN¹

Itch relief as soon as

48

hours

in some patients¹*

49% of patients achieved significant itch relief^† at Week 16 vs 16% with placebo (P<0.0001)^2,3‡

PP-NRS response was achieved at 48 hours in 17.2% with NEMLUVIO vs 3.7% with placebo. Data from pooled post-hoc analysis of daily PP-NRS improvement reported in Phase 3 clinical studies (OLYMPIA 1 and 2). PP-NRS response defined as a ≥4-point improvement from baseline. No conclusions regarding efficacy should be made based on these results.¹

Actor portrayal.

More than 9 out of 10 patients saw itch relief with nearly 2 years of treatment⁴

Graph image showing that 92% of NEMLUVIO® patients achieved continued itch improvement over 2 years.

Data based on interim analysis of patients with PP-NRS ≥4-point improvement at Week 100 of OLYMPIA LTE. No imputations for missing data.⁴

REVIEW STUDY DESIGN

Assessments & Scales

Peak PRURITUS Numerical Rating Scale (PP-NRS)⁵

Patient-reported outcome designed to measure the worst itch over the previous 24-hour period
Treatment success defined as at least a 4-point improvement from baseline

82%

of patients taking NEMLUVIO were itch‑free or nearly itch‑free with nearly 2 years of treatment⁴

Itch-free or nearly itch-free defined as PP-NRS <2⁴

Data based on interim analysis proportion of NEMLUVIO-naïve patients with PP-NRS <2 at Week 100 of the OLYMPIA LTE.⁴

Experiencing a new reality

See how Chris and Whitney relieved their unrelenting itch and achieved lasting skin healing with NEMLUVIO.

Transcript

Since starting the NEMLUVIO, I'm not itchy. Within two days I had noticed a significant improvement in the itch after starting the NEMLUVIO, and at that point it was pretty much gone.

I would definitely say that my disease was managed with NEMLUVIO at 4 weeks. My hands weren't cracked anymore, the areas around my eyes had healed.

The change has been hard to believe. In a good way. Basically, before the shot, itching was part of my reality.

I have not been itching since the first shot. After 1 month on NEMLUVIO, I have seen significant improvement in my itch.

Lasting Skin Healing⁴

Discover how NEMLUVIO healed most PN nodules for patients with PN⁴

SEE THE DIFFERENCE

Favorable Safety Profile²

NEMLUVIO offers a favorable safety profile and requires no preliminary lab evaluations or ongoing lab monitoring²

REVIEW SAFETY PROFILE

Sign up now for more information about NEMLUVIO for PN

SIGN UP

PP-NRS response defined as a ≥4-point improvement from baseline.²

Data shown from OLYMPIA 2; in OLYMPIA 1, 56% of patients achieved significant itch relief vs 16% for placebo.²

LTE=long-term extension; PN=prurigo nodularis; PP-NRS=Peak Pruritus Numerical Rating Scale.

References: 1. Ständer S, Elmariah SB, Kwatra SG, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. J Eur Acad Dermatol Venereol. 2025;00:1‑9. doi:10.1111/jdv.70250 2. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 3. Galderma Laboratories, L.P.; data on file. Clinical Study Report RD.06.SRE.203065 [OLYMPIA 2]; September 2023. 4. Legat FJ, Kwatra SG, Reich A, et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. J Eur Acad Dermatol Venereol. 2025;00:1–13. doi:10.1111/jdv.70266

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO^® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia.
Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.